Significantly longer time to deterioration of quality of life due to CANKADO PRO-React eHealth support in HR+ HER2- metastatic breast cancer patients receiving palbociclib and endocrine therapy: primary outcome analysis of the multicenter randomized AGO-B WSG PreCycle trial.
Ann Oncol
; 34(8): 660-669, 2023 08.
Article
en En
| MEDLINE
| ID: mdl-37201751
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Neoplasias de la Mama
Tipo de estudio:
Clinical_trials
Límite:
Female
/
Humans
/
Middle aged
Idioma:
En
Año:
2023
Tipo del documento:
Article